Summit Therapeutics SMMT Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's change in other liabilities?
- Summit Therapeutics (SMMT) reported change in other liabilities of -$33K in Q1 2026.
- How has Summit Therapeutics's change in other liabilities changed year-over-year?
- Summit Therapeutics's change in other liabilities decreased by 232.0% year-over-year, from $25K to -$33K.
- What does change in other liabilities mean?
- The change in miscellaneous liabilities that do not fall under standard accounts payable or accrued expenses.
- How do you interpret change in other liabilities?
- An increase provides a source of cash, whereas a decrease reflects the settlement or reduction of these miscellaneous obligations.
- How does change in other liabilities compare across companies?
- Varies significantly by company; often reflects specific accounting treatments for deferred income or long-term commitments.